Immusoft Corporation

Description

• Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP). The technology instructs a patients cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. Technical challenges, complex purification steps and frequent injections for patients are some of the challenges of biologic drug therapies. With small patient populations, rare diseases have significant commercial hurdles and can cost up to $400,000 per patient annually. Cell therapy with ISP is a better way to deliver biologic drug therapies.Immusoft has raised capital from the National Institutes of Health, Peter Thiel's Breakout Labs, Founders Fund Science, and prominent private investors, including Tim Draper and the former head of preclinical development at Seattle Genetics. We have exclusive rights to our core technology from Caltech and patent protection for our ISP platform until at least 2032. Immusoft will continue to work closely with prominent collaborators from the Fred Hutchinson Cancer Research Center in Seattle, and the University of Minnesota Medical Center to conduct our first human trials to treat MPS I. Preliminary human safety and efficacy data will permit expansion of Immusofts drug pipeline with additional ISP cell therapies.Immusoft was founded in 2009.
• 

  Headquarters:454 North 34th Street , Seattle, Washington, United States

  More
• 

  Phone Number: +1 206-931-0262

• 

  Website: https://www.immusoft.com

• 

  Employees:15

• 

  Revenue:$10 - 50M

• 

  Legal Name:Immusoft Corporation

• Immusoft Corporation's Social Media

  
• Is this data correct?

• |  NAICS Code: 541714  |

  Show More